Drugs / factor eight inhibitor bypassing activity
factor eight inhibitor bypassing activity
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02577614 | Feb 2016 → Dec 2019 | cardiovascular disorder | Oregon Health and Science University | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | factor eight inhibitor bypassing activity | “Factor eight inhibitor bypassing activity (FEIBA) is a prothrombin complex concentrate empirically used as rescue therapy for correction of refractory bleeding diathesis...” PMID 34215339 ↗ Jul 2021 |
| Known as | Factor VIII inhibitor bypass activity | “Factor VIII inhibitor bypass activity (FEIBA) for the reduction of transfusion in cardiac surgery: a randomized, double-blind, placebo-controlled, pilot trial.” NCT02577614 ↗ |
| Known as | FEIBA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02577614 ↗ |
| Action | Restore | “as it replenishes multiple depleted factors that are lost with prolonged exposure to CPB” NCT02577614 ↗ |
| Modality | Protein / enzyme biologic | “FEIBA is a prothrombin complex concentrate empirically used as rescue therapy” PMID 34215339 ↗ Jul 2021 |